"Herpesvirus 4, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
| Descriptor ID |
D004854
|
| MeSH Number(s) |
B04.280.210.400.500.450 B04.280.382.400.500.400 B04.613.204.500.500.400
|
| Concept/Terms |
Herpesvirus 4, Human- Herpesvirus 4, Human
- Burkitt Lymphoma Virus
- Lymphoma Virus, Burkitt
- Burkitt's Lymphoma Virus
- Burkitts Lymphoma Virus
- E-B Virus
- E B Virus
- E-B Viruses
- Infectious Mononucleosis Virus
- Infectious Mononucleosis Viruses
- Mononucleosis Virus, Infectious
- Mononucleosis Viruses, Infectious
- Epstein-Barr Virus
- Epstein Barr Virus
- Herpesvirus 4 (gamma), Human
- HHV-4
- Human Herpesvirus 4
- Burkitt Herpesvirus
- Herpesvirus, Burkitt
- EBV
|
Below are MeSH descriptors whose meaning is more general than "Herpesvirus 4, Human".
Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 4, Human".
This graph shows the total number of publications written about "Herpesvirus 4, Human" by people in this website by year, and whether "Herpesvirus 4, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 8 | 1 | 9 |
| 1996 | 4 | 5 | 9 |
| 1997 | 8 | 4 | 12 |
| 1998 | 11 | 7 | 18 |
| 1999 | 7 | 2 | 9 |
| 2000 | 6 | 4 | 10 |
| 2001 | 8 | 5 | 13 |
| 2002 | 11 | 11 | 22 |
| 2003 | 9 | 4 | 13 |
| 2004 | 8 | 10 | 18 |
| 2005 | 7 | 11 | 18 |
| 2006 | 6 | 6 | 12 |
| 2007 | 6 | 5 | 11 |
| 2008 | 6 | 8 | 14 |
| 2009 | 8 | 4 | 12 |
| 2010 | 7 | 4 | 11 |
| 2011 | 7 | 7 | 14 |
| 2012 | 4 | 6 | 10 |
| 2013 | 4 | 7 | 11 |
| 2014 | 4 | 6 | 10 |
| 2015 | 12 | 3 | 15 |
| 2016 | 5 | 6 | 11 |
| 2017 | 6 | 2 | 8 |
| 2018 | 4 | 7 | 11 |
| 2019 | 6 | 6 | 12 |
| 2020 | 3 | 5 | 8 |
| 2021 | 4 | 7 | 11 |
| 2022 | 2 | 13 | 15 |
| 2023 | 2 | 13 | 15 |
| 2024 | 4 | 5 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpesvirus 4, Human" by people in Profiles.
-
EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):728-735.
-
From the archives of MD Anderson Cancer Center: EBV-positive fibrin-associated large B-cell lymphoma in an ovarian leiomyoma with cystic degeneration: A case report and discussion of differential diagnosis. Ann Diagn Pathol. 2025 Feb; 74:152397.
-
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
-
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 07 09; 8(13):3360-3371.
-
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct; 99(10):2002-2015.
-
Noncanonical functions of telomerase and telomeres in viruses-associated cancer. J Med Virol. 2024 May; 96(5):e29665.
-
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood Adv. 2024 03 12; 8(5):1116-1127.
-
Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis. Mult Scler. 2024 Mar; 30(3):308-315.
-
Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through in vivo B cell knockout models. mBio. 2024 Feb 14; 15(2):e0299823.
-
Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay. Front Immunol. 2023; 14:1299512.